Lilly to Participate in Citi's 17th Annual BioPharma Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
It's Good to Be Eli Lilly (LLY) in 2022 Says Citi Analyst
August 25, 2022 3:18 PM EDTEli Lilly & Co. (NYSE: LLY) price target was raised to $370 from $285, with its Buy rating maintained at Citi on Thursday.
Analyst Andrew Baum stated in his research note that "it's good to be Lilly in 2022."
"We have increased our peak risk-adjusted tirzepatide... More
